Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months

Neurology

Volumn 59, Issue 4, 2002, Pages 563-572

  Darreh Shori, T ^a   Almkvist, O ^a   Guan, Z Z ^a   Garlind, A ^a   Strandberg, B ^a   Svensson, A L ^a   Soreq, H ^a   Hellstrom Lindahl E ^a   Nordberg, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; RIVASTIGMINE; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CEREBROSPINAL FLUID ANALYSIS; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; COLORIMETRY; DIARRHEA; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOBLOTTING; LONG TERM CARE; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SCORING SYSTEM; VOMITING;

EID: 0037183534     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.4.563     Document Type: Article

References (48)

1. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
2. Cholinesterase inhibitors stabilize Alzheimer disease
3. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease
4. Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors
5. Tacrine interacts with an allosteric activator site on alpha 4 beta 2 nAChRs in M10 cells
6. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor
7. Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications
8. Postnatal developmental delay and supersensitivity to organophosphate in genetargeted mice lacking acetylcholinesterase
9. Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons
10. Expression of a human acetylcholinesterase promoter-reporter construct in developing neuromuscular junctions of Xenopus embryos
11. Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins
12. Molecular and cellular biology of cholinesterases
13. Comparison of butyrylcholinesterase and acetylcholinesterase
14. Is acetylcholinesterase secreted from central neurons into the cerebral fluid?
15. Neurological cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability
16. RBC cholinesterase inhibition: A useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?
17. Activity of acetylcholinesterase in CSF increases in Alzheimer's patients after treatment with tacrine
18. Differential increase in cerebrospinal fluid acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
19. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
20. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans
21. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases
22. Acute stress facilitates long-lasting changes in cholinergic gene expression
23. Excess "read-through" acetylcholinesterase attenuates but the "synaptic" variant intensifies neurodeterioration correlates
24. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician
25. A new and rapid colorimetric determination of acetylcholinesterase activity
26. Antisense prevention of neuronal damages following head injury in mice
27. Episodic memory functioning in a community-based sample of old adults with major depression: Utilization of cognitive support
28. Age-related differences in neural activity during item and temporal-order memory retrieval: A positron emission tomography study
29. Frontal-subcortical circuits and human behavior
30. Brain structural and cognitive correlates of clock drawing performance in Alzheimer's disease
31. CSF cholinesterase activity in demented and nondemented subjects
32. Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type
33. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
34. Selective loss of central cholinergic neurons in Alzheimer's disease
35. Changes in brain cholinesterases in senile dementia of Alzheimer type
36. Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease
37. The cholinergic receptor system of the human brain: Neurochemical and pharmacological aspects in aging and Alzheimer
38. From molecular structure to Alzheimer therapy
39. Functional identity of catalytic subunits of acetylcholinesterase
40. Acetylcholinesterase from bovine caudate nucleus is attached to membranes by a novel subunit distinct from those of acetylcholinesterases in other tissues
41. Muscarinic acetylcholine receptors activate expression of the EGR gene family of transcription factors
42. Structural roles of acetylcholinesterase variants in biology and pathology
43. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease
44. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms
45. Anticholinesterases induce multigenic transcriptional feedback response suppressing cholinergic neurotransmission